Perrigo Approved for Generic Mycolog II Cream

Triamcinolone acetonide is mainly effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions.

Perrigo announced that the Food and Drug Administration (FDA)’s final approval for Nystatin and Triamcinolone Acetonide Cream USP, the generic version of Mycolog II Cream. 

Mycolog II Cream, a synthetic corticosteroid combined with a polyene antifungal, is indicated to treat cutaneous candidiasis. Nystatin exerts its antifungal activity against a variety of pathogenic and nonpathogenic yeasts and fungi by binding to sterols in the cell membrane. Triamcinolone acetonide is mainly effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions. 

Related Articles

Nystatin and Triamcinolone Acetonide Cream USP will be available as a 100,000 units/g and 1mg/g strength. It is anticipated to launch in the 4th quarter of 2017.

For more information call (866) 634-9120 or visit Perrigo.com.